冲刺200亿元收入,信达生物一款“减肥神药”可能要起大作用

医药研究社
Aug 04

GLP-1类药物“电商大战”或已打响。来源|医药研究社GLP-1类药物正成为信达生物冲刺200亿元道路上的“得力干将”。五年前,该公司在其内部战略会上提出了第二个十年的战略目标——2025年实现EBITDA(税息折旧及摊销前利润)转正,2027年实现200亿元的收入。如今,前一个目标已经提前实现,后一个目标则靠多个商业化产品加速兑现。目前,信达生物诸多上市产品中,引起不小关注甚至产生出圈效应的有...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10